- Author: Patricia Myriam Vuguin, MD, MSc; Chief Editor: Max J Coppes, MD, PhD, MBA more...
Pheochromocytoma is a rare catecholamine-secreting tumor that arises from chromaffin cells of the sympathetic nervous system (adrenal medulla and sympathetic chain); however, the tumor may develop anywhere in the body. Release of catecholamines into the circulation by these tumors causes significant hypertension. The classic clinical presentation includes paroxysmal attacks of headaches, pallor, palpitations, and diaphoresis.
Pheochromocytoma may be inherited as an autosomal dominant trait. Several genes (SDHD, SDHB, SDHC) that belong to the mitochondrial complex II have been identified as involved in the so-called pheochromocytoma-paraganglioma syndrome. (See Etiology.) The term paraganglioma refers to any extra-adrenal or nonfunctional tumor of the paraganglion system, whereas functional tumors are referred to as extra-adrenal pheochromocytomas.
Pheochromocytomas occur in both children and adults. In children, pheochromocytoma is more frequently associated with other familial syndromes, such as neurofibromatosis, von Hippel-Lindau disease, tuberous sclerosis, Sturge-Weber syndrome, and as a component of multiple endocrine neoplasia (MEN) syndromes (MEN 2A, MEN 2B). Familial cases are often bilateral or multicentric within an individual adrenal gland.
Adrenal pheochromocytomas are most often found on the right side and are sporadic, unilateral, and intra-adrenal. Approximately 6-10% of the tumors are malignant.
Usually, extra-adrenal tumors (extra-adrenal pheochromocytomas or paragangliomas) are located in the abdomen along the sympathetic chain and constitute about 10% of sporadic cases. Tumors have also been found in the neck, mediastinum, urinary bladder, and virtually every other site. Tumors vary from approximately 1-10 cm in diameter. Slowly growing metastases to bone, liver, lymph nodes, and lung can arise from malignant tumors.
Early diagnosis is important because the tumor may be fatal if undiagnosed, especially in pregnant women during delivery or in patients undergoing surgery for other disorders. Diagnosis can be made based on elevated levels of urinary catecholamines, but localization may require various modalities (see the images below, as well as Workup).
Treatment is with surgical removal. Chemotherapy and radiotherapy have been used in metastatic and unresectable pheochromocytoma, but their value is questionable. (See Treatment.)
For a discussion of pheochromocytoma in adults, see the Medscape Reference article Pheochromocytoma.
Pheochromocytoma is a tumor of neuroendocrine origin. In the fifth week of fetal development, neuroblastic cells migrate from the thoracic neural crest to form the sympathetic chains and preaortic ganglia. These cells are believed to be the precursors of neuroblastomas and ganglioneuromas.
Chromaffin cells migrate a second time to the adrenal medulla; the chromaffin cells settle near the sympathetic ganglia, the vagus nerve, paraganglia, and carotid arteries. Other, less common sites of extra-adrenal chromaffin tissues include the following:
Behind the liver
Catecholamine biosynthesis and metabolism
The pathophysiology of the pheochromocytoma is best appreciated with an understanding of catecholamine biochemistry.
The following is an abbreviated version of the important steps in the biosynthesis and metabolism of catecholamines:
Tyrosine → dihydroxyphenylalanine (DOPA) → dopamine (DA) → norepinephrine + epinephrine → homovanillic acid (HVA) + vanillylmandelic acid (VMA)
The biosynthesis and storage of catecholamines in chromaffin cell tumors may differ from the biosynthesis and storage in the normal medulla. However, the granules are morphologically and functionally similar to the granules from the adrenal medulla. The increase in tissue turnover suggests an alteration in the regulation of the catecholamine biosynthesis and possibly suggests an alteration in the feedback inhibition of tyrosine hydroxylase, the key enzyme in the production of catecholamines.
Catecholamines in pheochromocytomas
Pheochromocytomas, unlike the normal adrenal medulla, are not innervated, and catecholamine release is not initiated by neural impulses. Changes in direct flow, pressure, chemicals, drugs, and angiotensin II may initiate the release of catecholamines into the circulation.
Most pheochromocytomas in children predominantly produce norepinephrine, unlike the normal adrenal medulla, which, in humans, contains 85% epinephrine. Rarely, tumors produce epinephrine exclusively; in some cases, the clinical picture is dominated by signs of beta-receptor stimulation, such as tachycardia and hypermetabolism. However, in most cases, predicting the pattern of catecholamine secretion based on the clinical picture is impossible.
The actions of catecholamines are mediated by the alpha-adrenergic and beta-adrenergic receptors. Alpha1 receptors cause arteriolar constriction. Alpha2 receptors mediate the presynaptic feedback inhibition of norepinephrine release and decrease insulin secretion.
Beta1 receptors increase cardiac rate and contractility. Beta2 receptors cause arteriolar and venous dilation and relaxation of tracheobronchial smooth muscle. The symptoms associated with pheochromocytomas are caused by the physiologic and pharmacologic effects of large amounts of circulating norepinephrine and epinephrine.
Pheochromocytomas in patients with von Hippel-Lindau syndrome and MEN type 2 differ in the types and amounts of catecholamines produced and the resulting signs and symptoms. Eisenhofer et al reported that the rate constant for baseline catecholamine secretion was 20-fold higher from tumors in von Hippel-Lindau syndrome (n = 47) than from MEN2 tumors (n = 32), but catecholamine release in response to glucagon occurred only in MEN2 tumors.
Thus, the differences in catecholamine release may contribute to clinical differences in the secretion of neurotransmitters or hormones and the subsequent clinical presentation.
Over the last 2 decades, various mouse and rat models have been created presenting with pheochromocytomas, which include models presenting tumors that are to a certain degree biochemically and/or molecularly similar to human pheochromocytomas and develop metastases. In addition, cell lines such as mouse pheochromocytoma (MPC) and mouse tumor tissue (MTT) cells have been recently introduced and they both showed metastatic behavior. It appears these MPC and MTT cells are biochemically and molecularly similar to some human pheochromocytomas, are easily visualized, and respond to different therapies.
Pheochromocytoma is inducible in rats by various nongenotoxic substances that may act indirectly by stimulating chromaffin cell proliferation. The nerve growth factor-responsive PC12 cell line, established from a rat pheochromocytoma, has served as a research tool for almost 30 years for many aspects of neurobiology involving normal and neoplastic conditions.
Pheochromocytoma cell lines from neurofibromatosis knockout mice supplement the PC12 line and have generated additional applications. Two mice models of metastatic pheochromocytoma have been established: one used tail vein injection of mouse pheochromocytoma cells ; the other involved the conditional knockout of the pten protein. Thus, the use of mouse models allows further study into the pathogenesis of human malignant pheochromocytoma and into therapeutic strategies for these tumors.
Bone lesions have been described following changes in the microcirculation.
Myocarditis characterized by focal degeneration and necrosis of myocardial fibers with infiltration of histiocytes, plasma cells, and other signs of inflammation may be present.
Chronic constriction of the arterial and venous beds leads to a reduction in plasma volume. The inability to further constrict the bed upon arising results in postural hypotension.
Pheochromocytoma occurs wherever chromaffin tissue is found. Mutations in genes that code for 3 of the 4 components of mitochondrial complex II can cause paragangliomas and pheochromocytomas. The 3 genes involved are SDHB, SDHC, and SDHD.
Of the 4 components of mitochondrial complex II (succinate dehydrogenase [SDH] A, B, C, and D), SDHC and SDHD anchor the catalytic subunits SDHA and SDHB in the inner mitochondrial membrane. SDHD is maternally imprinted, whereas SDHB and SDHC are not. Although SDHD and, to a lesser degree, SDHB mutations have been found in many cases of hereditary paragangliomas, SDHC mutations are rare.
Amar et al delineated causes of pheochromocytoma in a study of 314 patients with pheochromocytoma or functional paraganglioma. Fifty six patients had family history, syndromic disease, or both, and 258 patients had sporadic presentation. Among the 56 patients with a family history, syndromic presentation, or both, 13 had neurofibromatosis type 1, and 43 had germline mutations on the VHL, RET, SDHD, or SDHB genes (16, 15, 9, and 3 patients, respectively).
Only 11% of the patients with sporadic disease had a germline mutation (18 patients had a SDHB mutation, 9 patients had a VHL mutation, 2 patients had a SDHD mutation, and 1 patient had a RET mutation). Mutation carriers were young and frequently had bilateral or extra-adrenal tumors. In patients with an SDHB mutation, the tumors were larger, usually extra-adrenal, and malignant.
Pheochromocytomas are usually sporadic, but they may be familial and appear as a component of other syndromes, such as MEN 2A (medullary thyroid carcinoma, parathyroid hyperplasia, pheochromocytoma). Germline mutations of the ret proto-oncogene on chromosome 10 (10q11.2) have been found in families with MEN 2A and MEN 2B (medullary thyroid carcinoma, neuromas, pheochromocytoma).
In von Hippel-Lindau syndrome, specific mutations determine the varied clinical manifestations, which, in addition to pheochromocytomas, include retinal angiomas; cerebellar hemangioblastomas; and renal, pancreatic, and epididymal tumors. A germline mutation in a tumor suppressor gene on chromosome 3 has been identified.
Pheochromocytoma is also associated with tuberous sclerosis, Sturge-Weber syndrome, and ataxia-telangiectasia.
In the United States, the reported annual incidence rate of pheochromocytomas is approximately 1 per 100,000 population, with 10-20% of cases occurring in children or adolescents. The frequency of bilateral tumors is higher in children than in adults (20% vs 5-10%), while that of malignant tumors is lower (3.5% vs 3-14%). More than one third of affected children have multiple tumors, most of which are recurrent.
In children, 70% of cases are unilateral, 70% of cases are confined to adrenal locations, and an increased association with familial syndromes is noted. In 30-40% of children with pheochromocytomas, tumors are found in both adrenal and extra-adrenal areas or in only extra-adrenal areas.
Race-, sex-, and age-related demographics
Pheochromocytomas have been described in Japanese, Chinese, black, European, and white families. No geographic predilection is known.
Although pheochromocytomas are found in both sexes, the male-to-female ratio is 2:1. In a study by Lai et al, female patients have significantly more self-reported pheochromocytoma signs and symptoms compared with males; these include the following :
Headache (80% vs 52%)
Dizziness (83% vs 39%)
Anxiety (85% vs 50%)
Tremor (64% vs 33%)
Weight change (88% vs 43%)
Numbness (57% vs 24%)
Changes in energy level (89% vs 64%)
In childhood, pheochromocytomas present most frequently in children aged 6-14 years (average, 11 y).
A recent study that identified 41 subjects with metastatic pheochromocytomas and compared them with 108 subjects with apparently benign pheochromocytomas showed that metastatic pheochromocytomas presented at a significantly younger age (41.4 ±14·7 y vs 50.2 ±13.7 y; P < .001), were larger (8.38 ±3·27 cm vs 6·18 ±2.75 cm; P < .001), had more frequent secretion of norepinephrine, and had a higher occurrence of necrosis.
The prognosis in patients with pheochromocytomas appears to be related to tumor size, degree of uncontrolled hypertension, and the presence of metastatic disease.
Uncontrolled hypertension may lead to serious, even fatal, morbidity, such as the following:
Dissecting aortic aneurysm
Special consideration must be given to prepare these patients for surgery, because dramatic blood pressure swings may be observed.
Malignant pheochromocytomas, which are rare in children, are locally invasive and may spread to distant areas that do not contain chromaffin cells, including the liver, lung, bone, and lymph nodes. The mean 5-year survival rate in patients with malignant pheochromocytomas is 40%.
A study by Khorram-Manesh et al of the long-term outcome in Swedish patients who underwent surgical treatment of pheochromocytoma from 1950-1997 found that over 15 (±6) years, 42 patients died, compared with 23.6 deaths expected in the general population. Besides older age at primary surgery, elevated urinary excretion of methoxy-catecholamines was the only observed mortality risk factor. Preoperative and postoperative hypertension did not influence the mortality risk compared with controls.
A retrospective study by Timmers et al in the Netherlands documented that metastases, but not cardiovascular mortality, reduced life expectancy in 69 patients who had undergone surgical resection of apparently benign pheochromocytoma. Kaplan-Meier estimates for 5-year and 10-year survival since surgery were 85.8% and 74.2% for patients compared with 95.5% and 89.4% in the reference population.
Two patients died of surgical complications. All 10 patients with metastatic disease died, including 3 diagnosed at first surgery. At follow-up, 40 patients were alive and recurrence-free, and 3 patients were lost to follow up. Two patients experienced a benign recurrence. A significant decrease in blood pressure was observed in 64% of patients with hypertension prior to surgery; however, they remained hypertensive after surgery.
Pheochromocytoma during pregnancy represents a condition with potentially high maternal and fetal mortality. However, in current practice, pheochromocytoma in pregnancy is recognized earlier, and, in conjunction with improved medical management, maternal mortality has decreased to less than 5%.
Waguespack SG, Rich T, Grubbs E, et al. A current review of the etiology, diagnosis, and treatment of pediatric pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2010 May. 95(5):2023-37. [Medline].
Eisenhofer G, Huynh TT, Elkahloun A, Morris JC, Bratslavsky G, Linehan WM. Differential expression of the regulated catecholamine secretory pathway in different hereditary forms of pheochromocytoma. Am J Physiol Endocrinol Metab. 2008 Nov. 295(5):E1223-33. [Medline]. [Full Text].
Korpershoek E, Pacak K, Martiniova L. Murine models and cell lines for the investigation of pheochromocytoma: applications for future therapies?. Endocr Pathol. 2012 Mar. 23(1):43-54. [Medline]. [Full Text].
Tischler AS, Powers JF, Alroy J. Animal models of pheochromocytoma. Histol Histopathol. 2004 Jul. 19(3):883-95. [Medline].
Martiniova L, Lai EW, Elkahloun AG, Abu-Asab M, Wickremasinghe A, Solis DC. Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific gene signature. Clin Exp Metastasis. 2009. 26(3):239-50. [Medline].
Korpershoek E, Loonen AJ, Corvers S, van Nederveen FH, Jonkers J, Ma X. Conditional Pten knock-out mice: a model for metastatic phaeochromocytoma. J Pathol. 2009 Mar. 217(4):597-604. [Medline].
Amar L, Bertherat J, Baudin E, et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol. 2005 Dec 1. 23(34):8812-8. [Medline].
Lai EW, Perera SM, Havekes B, Timmers HJ, Brouwers FM, McElroy B. Gender-related differences in the clinical presentation of malignant and benign pheochromocytoma. Endocrine. 2008 Aug-Dec. 34(1-3):96-100. [Medline].
Khorram-Manesh A, Ahlman H, Nilsson O, et al. Long-term outcome of a large series of patients surgically treated for pheochromocytoma. J Intern Med. 2005 Jul. 258(1):55-66. [Medline].
Timmers HJ, Brouwers FM, Hermus AR, Sweep FC, Verhofstad AA, Verbeek AL, et al. Metastases but not cardiovascular mortality reduces life expectancy following surgical resection of apparently benign pheochromocytoma. Endocr Relat Cancer. 2008 Dec. 15(4):1127-33. [Medline].
Prejbisz A, Lenders JW, Eisenhofer G, Januszewicz A. Mortality associated with phaeochromocytoma. Horm Metab Res. 2013 Feb. 45(2):154-8. [Medline].
Prejbisz A, Lenders JW, Eisenhofer G, Januszewicz A. Cardiovascular manifestations of phaeochromocytoma. J Hypertens. 2011 Aug 5. [Medline].
Yu R, Nissen NN, Chopra P, Dhall D, Phillips E, Wei M. Diagnosis and treatment of pheochromocytoma in an academic hospital from 1997 to 2007. Am J Med. 2009 Jan. 122(1):85-95. [Medline].
Zeiger MA, Siegelman SS, Hamrahian AH. Medical and surgical evaluation and treatment of adrenal incidentalomas. J Clin Endocrinol Metab. 2011 Jul. 96(7):2004-15. [Medline].
Pamporaki C, Därr R, Bursztyn M, et al. Plasma-free vs deconjugated metanephrines for diagnosis of phaeochromocytoma. Clin Endocrinol (Oxf). 2013 Mar 5. [Medline].
Hickman PE, Leong M, Chang J, Wilson SR, McWhinney B. Plasma free metanephrines are superior to urine and plasma catecholamines and urine catecholamine metabolites for the investigation of phaeochromocytoma. Pathology. 2009 Feb. 41(2):173-7. [Medline].
Boyle JG, Davidson DF, Perry CG, Connell JM. Comparison of diagnostic accuracy of urinary free metanephrines, vanillyl mandelic Acid, and catecholamines and plasma catecholamines for diagnosis of pheochromocytoma. J Clin Endocrinol Metab. 2007 Dec. 92(12):4602-8. [Medline].
Giovanella L, Ceriani L, Balerna M, Keller F, Taborelli M, Marone C, et al. Diagnostic value of serum chromogranin-A combined with MIBG scintigraphy inpatients with adrenal incidentalomas. Q J Nucl Med Mol Imaging. 2008 Mar. 52(1):84-88. [Medline].
Imani F, Agopian VG, Auerbach MS, Walter MA, Imani F, Benz MR. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas. J Nucl Med. 2009 Apr. 50(4):513-9. [Medline].
Fiebrich HB, Brouwers AH, van Bergeijk L, van den Berg G. Image in endocrinology. Localization of an adrenocorticotropin-producing pheochromocytoma using 18F-dihydroxyphenylalanine positron emission tomography. J Clin Endocrinol Metab. 2009 Mar. 94(3):748-9. [Medline].
Kauhanen S, Seppanen M, Ovaska J, Minn H, Bergman J, Korsoff P. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors. Endocr Relat Cancer. 2009 Mar. 16(1):255-65. [Medline].
Zelinka T, Timmers HJ, Kozupa A, et al. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations. Endocr Relat Cancer. 2008 Mar. 15(1):311-23. [Medline].
Dannenberg H, van Nederveen FH, Abbou M, et al. Clinical characteristics of pheochromocytoma patients with germline mutations in SDHD. J Clin Oncol. 2005 Mar 20. 23(9):1894-901. [Medline].
Erlic Z, Neumann HP. When should genetic testing be obtained in a patient with phaeochromocytoma or paraganglioma?. Clin Endocrinol (Oxf). 2009 Mar. 70(3):354-7. [Medline].
Jimenez C, Cote G, Arnold A, Gagel RF. Should Patients with Apparently Sporadic Pheochromocytomas or Paragangliomas be Screened for Hereditary Syndromes?. J Clin Endocrinol Metab. 2006 May 30. [Medline]. [Full Text].
Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002 May 9. 346(19):1459-66. [Medline].
Currás-Freixes M, Inglada-Pérez L, Mancikova V, et al. Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients. J Med Genet. 2015 Aug 12. [Medline].
Brouwers FM, Petricoin EF 3rd, Ksinantova L, Breza J, Rajapakse V, Ross S, et al. Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma. Endocr Relat Cancer. 2005 Jun. 12(2):263-72. [Medline].
Suh I, Shibru D, Eisenhofer G, Pacak K, Duh QY, Clark OH, et al. Candidate genes associated with malignant pheochromocytomas by genome-wide expression profiling. Ann Surg. 2009 Dec. 250(6):983-90. [Medline].
Brouwers FM, Elkahloun AG, Munson PJ, et al. Gene expression profiling of benign and malignant pheochromocytoma. Ann N Y Acad Sci. 2006 Aug. 1073:541-56. [Medline].
Rattenberry E, Vialard L, Yeung A, et al. A comprehensive next generation sequencing based genetic testing strategy to improve diagnosis of inherited pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2013 May 10. [Medline].
Gosse P, Tauzin-Fin P, Sesay MB, Sautereau A, Ballanger P. Preparation for surgery of phaeochromocytoma by blockade of alpha-adrenergic receptors with urapidil: what dose?. J Hum Hypertens. 2009 Sep. 23(9):605-9. [Medline].
Shonkwiler RJ, Lee JA. Laparoscopic retroperitoneal adrenalectomy. Surg Laparosc Endosc Percutan Tech. 2011 Aug. 21(4):243-7. [Medline].
[Guideline] International Pediatric Endosurgery Group. IPEG guidelines for the surgical treatment of adrenal masses in children. J Laparoendosc Adv Surg Tech A. 2010 Mar. 20(2):vii-ix. [Medline].
St Peter SD, Valusek PA, Hill S, et al. Laparoscopic adrenalectomy in children: a multicenter experience. J Laparoendosc Adv Surg Tech A. 2011 Sep. 21(7):647-9. [Medline].
Huang H, Abraham J, Hung E, Averbuch S, Merino M, Steinberg SM. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer. 2008 Oct 15. 113(8):2020-8. [Medline].
Joshua AM, Ezzat S, Asa SL, Evans A, Broom R, Freeman M. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. J Clin Endocrinol Metab. 2009 Jan. 94(1):5-9. [Medline].
Park KS, Lee JL, Ahn H, Koh JM, Park I, Choi JS. Sunitinib, a novel therapy for anthracycline- and cisplatin-refractory malignant pheochromocytoma. Jpn J Clin Oncol. 2009 May. 39(5):327-31. [Medline].
Jimenez C, Cabanillas ME, Santarpia L, Jonasch E, Kyle KL, Lano EA. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab. 2009 Feb. 94(2):386-91. [Medline].
Jimenez C, Rohren E, Habra MA, et al. Current and Future Treatments for Malignant Pheochromocytoma and Sympathetic Paraganglioma. Curr Oncol Rep. 2013 May 15. [Medline].